Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 16/20 | 0.49 |
| ▸ | ADRA1A | P35348 | 16/20 | 0.49 |
| ▸ | ADRA1B | P35368 | 16/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6198559 | 0.85 | ADRA1D (0.53) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6197607 | 0.83 | ADRA1D (0.46) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6792992 | 0.81 | PDE1C (0.45) | ADRA1DADRA1AADRA1BPDE1CMAPT | |
| SCHEMBL6199413 | 0.75 | PKM (0.52) | POLB | |
| SCHEMBL6791270 | 0.74 | GAA (0.49) | POLB | |
| SCHEMBL6245301 | 0.74 | ADRA1D (0.53) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6712135 | 0.73 | PDE1C (0.39) | ADRA1DADRA1AADRA1BPDE1CMAPT | |
| SCHEMBL7665729 | 0.72 | ADRA1D (0.47) | ADRA1DADRA1AADRA1BPDE1CMAPT | |
| SCHEMBL6782643 | 0.72 | ADRA1D (0.68) | ADRA1DADRA1AADRA1B | |
| SCHEMBL6199524 | 0.70 | ADRA1D (0.67) | ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1021185-A4 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 2005-09-07 | — | — | EP | disclosed |
| US-6727257-B1 | HYPOTENSIVE AGENTS FOR INTRAOCULAR PRESSURE; ANTICHOLESTEROL AGENTS; RELAXING URINARY TRACT TISSUE; BENIGN PROSTATIC HYPERPLASIA, IMPOTENCY, AND CARDIOVASCULAR DISORDERS; ANTIARRHYTHMIA AGENTS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2004-04-27 | — | — | US | disclosed |
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | SYNAPTIC PHARMACEUTICAL CORPORATION | 2002-01-24 | — | — | US | disclosed |
| US-6268369-B1 | ALPHA SUB 1 INHIBITORS | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-07-31 | — | — | US | disclosed |
| US-6245773-B1 | BENIGN PROSTATIC HYPERPLAMIA; REDUCTION OF INTRAOCULAR PRESSURE | SYNAPTIC PHARMACEUTICAL CORPORATION | 2001-06-12 | — | — | US | disclosed |
| EP-1021185-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 2000-07-26 | — | — | EP | disclosed |
| EP-0790826-A4 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMA CORP (US) | 1998-11-11 | — | — | EP | disclosed |
| WO-1997042956-A1 | DIDHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-11-20 | — | — | WO | disclosed |
| EP-0790826-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1997-08-27 | — | — | EP | disclosed |
| WO-1996014846-A1 | DIHYDROPYRIMIDINES AND USES THEREOF | SYNAPTIC PHARMACEUTICAL CORPORATION (US) | 1996-05-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020010186-A1 | Dihydropyrimidines and uses thereof | QDPR, DPYD, ADRA1D | ADRA1D 3/4885ADRA1A 4/4885ADRA1B 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.